Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT00442507
Phase
PHASE2
Status
Terminated

Conditions

  • Esophageal Diseases
  • Esophageal Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Determine the time to progression for the combination of erlotinib and bevacizumab in patients with previously treated metastatic cancer of the esophagus or gastroesophageal junction

Key Dates

First listed
Mar 2, 2007
Start date
Mar 31, 2007
Status verified
Jul 2015
Primary completion
Jan 31, 2009
Completion
Jan 31, 2009

Study Design

Enrollment
6 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Patients will be treated with erlotinib 150 mg oral daily and Avastin 15 mg/kg intravenously each cycle of therapy (each cycle is 21 days or every 3 weeks). The first infusion of Avastin will be administered over 90 minutes. If tolerated, the second infusion will be given over 60 minutes and in 30 minutes for the subsequent treatments. Treatment will be administered until disease progression or intolerable side effects.

Primary Outcome Measure

Time to Progression (TTP) [ Time Frame: Median follow-up for TTP 6 weeks (6-18 weeks) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63110-

Find similar trials in St Louis, MO

By research site
Washington University School of Medicine· St Louis, MO

Related Studies